TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2422467
Drug: placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (20 ml 0.9% NaCl)
Study: 31575503
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 and carboplatin (AUC 2 μg×h/mL) on days 1 and 8 (group 1)
Study: 31575503
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m2 on days 1 and 8 (group 2)
Study: 28464321
Drug: DS-3801b 50
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-3801b 50 mg
Study: 23556466
Drug: Early-invitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-invitation group (food supplements starting at ∼9 weeks gestation, 2.5 MJ d(‐1), 6 days a week)
Study: 23556466
Drug: Usual-invitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-invitation group (food supplements starting at ∼20 weeks gestation)
Study: 17309935
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D supplementation (500 mg calcium carbonate with 200 IU vitamin D twice daily)
Study: 12184523
Drug: Synthetic motilin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic motilin infusion
Study: 15985559
Drug: Anti-H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H pylori treatment
Study: 9536937
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for one month followed by 20 mg/day for six months
Study: 7634631
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for 7 days postoperatively
Study: 7634631
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no non-steroidal antiinflammatory drug)
Study: 869151
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0‐125% or 0‐25% bupivacaine solutions
Study: 25941160
Drug: Linagliptin with
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin with insulin (mild renal impairment)
Study: 25941160
Drug: Linagliptin with
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin with insulin (moderate renal impairment)
Study: 25941160
Drug: Linagliptin with
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin with insulin (severe renal impairment)
Study: 22470030
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (β‐carotene, vitamin C, vitamin E)
Study: 11341475
Drug: Tolterodine 2mg
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine 2mg twice daily
Study: 11341475
Drug: Oxybutynin 5mg
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin 5mg 3 times daily
Study: 11341475
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily extended-release tolterodine capsules
Study: 9022531
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil concentrate (FOC) 5 g
Study: 9022531
Drug: Purified eicosapentaenoic
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified eicosapentaenoic acid (EPA) 3 g
Study: 9022531
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil ethyl esters) 5 g
Study: 7889665
Drug: Ro 24-0238,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 24-0238, 10% solution in diethylene glycol monoethyl ether
Study: 3065929
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone (CFT) 100 mg/kg once daily
Study: 3065929
Drug: Combined intramuscular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intramuscular ampicillin (160 mg/kg/day) and chloramphenicol (100 mg/kg/day) given every 6 h (AMC)
Study: 3065929
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone (CFT)
Study: 3065929
Drug: Combined intramuscular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intramuscular ampicillin and chloramphenicol (AMC)
Study: 24430534
Drug: rilpivirine 25
Normalized name: rilpivirine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilpivirine 25 mg once daily
Study: 21150563
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg once daily
Study: 22621465
Drug: New methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: New methadone formulation
Study: 22621465
Drug: Previous reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous reference formulation of methadone
Study: 18717675
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 308-nm excimer laser phototherapy and topical hydrocortisone 17-butyrate cream
Study: 11844898
Drug: Cafergot (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafergot (1 mg ergotamine tartrate with 100 mg caffeine)
Study: 11844898
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of eletriptan
Study: 7588662
Drug: Intravenous maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous maintenance anaesthesia (alfentanil infusion 1-1.5 micrograms kg‐1 min‐1, midazolam injections 2.5-5 mg h‐1)
Study: 3510384
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (125 mg)
Study: 12815771
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia
Study: 7248984
Drug: Postmastectomy chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmastectomy chemotherapy for 2 years
Study: 16160710
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day mifepristone for 8 days
Study: 8713566
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group cC (10 not-AT-treated BP patients)
Study: 27529839
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab (IVR) monotherapy
Study: 19490053
Drug: Rufinamide 1600
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rufinamide 1600 mg twice daily
Study: 15221244
Drug: P. niruri
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. niruri (450 mg capsules, td)
Study: 3503108
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered haloperidol
Study: 3503108
Drug: Topical medications
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medications in glaucomatous patients
Study: 26233764
Drug: Numerical skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Numerical skills training program (twice a week for 2 months, 30 minutes per session)
Study: 20467418
Drug: Rosiglitazone (ROSI)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (ROSI) 8 mg daily
Study: 18297434
Drug: Oral EGD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EGD
Study: 16554952
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (800 IU daily)
Study: 12888186
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (6.6 g/day)
Study: 14576756
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily supplementation with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B6 for 4 months
Study: 10526245
Drug: TRH (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (200 microg, intravenously administered)
Study: 8913433
Drug: Oral ftorafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ftorafur (370 mg/m2) and leucovorin (20 mg/m2)
Study: 1895471
Drug: Continuous 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 2.0 mg/h morphine infusion
Study: 1895471
Drug: Continuous 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 0.5 to 2 mg/h morphine infusion
Study: 1895471
Drug: No morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No morphine infusion (control group)
Study: 30790163
Drug: Intraperitoneal instillation
Normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation of 40 ml bupivacaine 0.25%
Study: 26908302
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (ITS) 40 µg/dose
Study: 26908302
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia (PCA) 1 mg/dose
Study: 23529273
Drug: Post-dialysis dosing
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-dialysis dosing of cinacalcet (group AD) administered 3 times/week by dialysis staff.
Study: 23529273
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home administration of cinacalcet (group D).
Study: 23529273
Drug: Post-dialysis dosing
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-dialysis dosing of cinacalcet (group AD) in patients with less severe SHPT.
Study: 23529273
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home administration of cinacalcet (group D) in patients with less severe SHPT.
Study: 17340186
Drug: Multidimensional Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Treatment Foster Care Program for Preschoolers (MTFC-P)
Study: 16287602
Drug: Purified mistletoe
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified mistletoe lectin (ML)
Study: 16287602
Drug: Mistletoe plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe plant extract IQ depleted from ML
Study: 9804681
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied emulsion of an analgesic ammonium solution
Study: 2695549
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (Ca) supplementation 1.5 g daily for 12 weeks
Study: 2695549
Drug: Calcium (Ca)
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (Ca) supplementation 1 g daily for 8 weeks
Study: 321087
Drug: Levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 150 mg/day for three consecutive days every fortnight (study 1 and first half of study 2)
Study: 31677995
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method of vacuum assisted wound closure for 8 weeks; dressing changed 3 times weekly, at 125 mmHg, mode of 2 min off and 5 min on.
Study: 29462456
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2700 mg/day for 6 months
Study: 26289436
Drug: Leucine at
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine at 0.45 kcal/min (total 9.9 g, 40.5 kcal)
Study: 26289436
Drug: Leucine at
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine at 0.15 kcal/min (total 3.3 g, 13.5 kcal)
Study: 19047026
Drug: Oral hypoglycemics
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemics
Study: 12767415
Drug: amoxicillin/clavulanate
Normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin/clavulanate
Study: 8995350
Drug: Dios (Daflon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dios (Daflon 500 mg)
Study: 8127216
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w vaccine (initial dose)
Study: 8127216
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w vaccine (booster dose)
Study: 8127216
Drug: Placebo (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initial dose)
Study: 8127216
Drug: Placebo (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (booster dose)
Study: 3306131
Drug: Sandwich chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich chemotherapy (administered between surgery and postoperative irradiation)
Study: 3306131
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with CCNU and vincristine
Study: 3306131
Drug: Sandwich chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich chemotherapy (as administered)
Study: 3306131
Drug: Reduced radiotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced radiotherapy doses to the supratentorial area and to the spine in low risk patients
Study: 2397975
Drug: Pulsed electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed electrical field treatment administered over 36 weeks
Study: 4922754
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 15 mg daily
Study: 21164355
Drug: hApoA-I overexpression
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: hApoA-I overexpression via intraportal/vector administration
Study: 21164355
Drug: hApoA-I overexpression
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: hApoA-I overexpression via intramuscular/vector administration
Study: 19111806
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy, chemotherapy, or a combination
Study: 17910225
Drug: Adhesive patch
Normalized name: ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive patch applied to Class II cavities
Study: 17910225
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fillings without patch application)
Study: 12027046
Drug: D-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fenfluramine (30 mg p.o.)
Study: 8917239
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lidocaine/prilocaine (EMLA) cream
Study: 6355269
Drug: C.B.S. tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.B.S. tablets (1 four times daily)
Study: 6355269
Drug: C.B.S. liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.B.S. liquid (5 ml four times daily)
Study: 6355269
Drug: C.B.S. tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.B.S. tablets and liquid
Study: 22014267
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN)
Study: 22014267
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SE)
Study: 22014267
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing unloaded fraction (SS)
Study: 22014267
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing gallic acid loaded in non-elastic niosomes (GN)
Study: 22014267
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing gallic acid loaded in elastic niosomes (GE)
Study: 22014267
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN and SE)
Study: 11000320
Drug: Bioadhesive fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive fluoride tablets (0.5 mg F) used for 5 days
Study: 11000320
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fluoride supplements) for 5 days
Study: 1395766
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole (up to 0.84 mg/kg in 10 min)
Study: 1395766
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole (300 mg of pulverized tablets)
Study: 2082492
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole
Study: 3901172
Drug: Sucralfate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (300 mg daily)
Study: 3901172
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg daily)
Study: 29665829
Drug: HeLP-her program
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeLP-her program (one group session, monthly SMS text messages, one phone coaching session, and a program manual)
Study: 22721642
Drug: LSM+miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSM+miglitol (50 mg × 3)
Study: 18504332
Drug: Survey on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey on knowledge about ACS symptoms and treatment
Study: 9223837
Drug: Dronabinol 2.5
Normalized name: dronabinol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 2.5 mg twice daily (90%) or 2.5 mg once daily (10%)
Study: 3526773
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ampicillin, mecillinam and metronidazole (group I)
Study: 27909310
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (historical control)
Study: 24610862
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg once-daily
Study: 25092441
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg once-daily
Study: 23850394
Drug: Mirabegron (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (both doses)
Study: 18822498
Drug: Vaccine against
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine against Haemophilus influenzae type b administered simultaneously with diphtheria-tetanus-whole cell pertussis and inactivated polio vaccines (Imovax Polio)
Study: 18822498
Drug: Vaccine against
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine against Haemophilus influenzae type b
Study: 16912120
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 25, 50, 125, 300, or 600 mg weekly for 5 months
Study: 16912120
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 125, 300, and 600 mg
Study: 12522515
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 or 400 mg/d
Study: 12522515
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 to 400 mg/d
Study: 16681880
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg/d
Study: 2527130
Drug: Human lente
Normalized name: INSULIN HUMAN LENTE 100 UNIT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human lente insulin
Study: 29059273
Drug: Tasquinimod (0.25-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasquinimod (0.25-1.0 mg/day orally)
Study: 23945520
Drug: 0.5 cc
Normalized name: SureComfort Pen 30g, 0.5 cc, 5/16 inches
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 cc mDHACM
Study: 23945520
Drug: 1.25 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 cc mDHACM
Study: 23945520
Drug: Control (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1.25 cc saline)
Study: 17892885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EX/RP and CMI (EX/RP&CMI)
Study: 14622688
Drug: Caffeine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (10 mg x kg(‐1) body weight)
Study: 8460916
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg orally every 12 h)
Study: 28018112
Drug: Capsaicin infusion
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin infusion
Study: 25580060
Drug: roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (150 mg/day for 6 months)